



# SAGE GATESHEAD

CONFERENCE OVERVIEW  
15–18 SEPTEMBER 2018



Clinical & Scientific  
Update 2018

---

Scientific Programme

---

[eta2018.org](http://eta2018.org)

**The CONGRESS REGISTRATION DESK will operate the following hours:**

<b>FRIDAY,</b>	<b>14th Sept.</b>	<b>16.00 – 18.00</b>
<b>SATURDAY,</b>	<b>15th Sept.</b>	<b>07.00 – 19.30</b>
<b>SUNDAY,</b>	<b>16th Sept.</b>	<b>06.30 – 18.45</b>
<b>MONDAY,</b>	<b>17th Sept.</b>	<b>06.30 – 19.15</b>
<b>TUESDAY,</b>	<b>18th Sept.</b>	<b>06.30 – 15.00</b>

**COMMERCIAL EXHIBITION Opening times**

<b>SATURDAY,</b>	<b>15th Sept.</b>	<b>09.00 – 18.00</b>
<b>SUNDAY,</b>	<b>16th Sept.</b>	<b>09.00 – 18.00</b>
<b>MONDAY,</b>	<b>17th Sept.</b>	<b>09.00 – 18.00</b>
<b>TUESDAY,</b>	<b>18th Sept.</b>	<b>09.00 – 15.00</b>

**MEDIA CHECK Opening times**

<b>SATURDAY,</b>	<b>15th Sept.</b>	<b>07.00 – 18.15</b>
<b>SUNDAY,</b>	<b>16th Sept.</b>	<b>06.30 – 18.00</b>
<b>MONDAY,</b>	<b>17th Sept.</b>	<b>06.30 – 18.00</b>
<b>TUESDAY,</b>	<b>18th Sept.</b>	<b>06.30 – 13.00</b>

The 41st ANNUAL MEETING of the European Thyroid Association has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximum of 26 European CME credits (ECMEC®s).

# ETA Clinical Update

## Primary Hyperthyroidism

VENUE  
**SAGE One**

08.00 – 13.00

Chair: Thomas Brix (Denmark) & Tomasz Bednarczuk (Poland)

08.00-08.30 **Epidemiology, clinical picture, and diagnosis of hyperthyroidism**  
*Mark Vanderpump (United Kingdom)*

08.30-09.00 **Treatment options in hyperthyroidism and how to monitor / evaluate the effect of treatment**  
*Maria Alevizaki (Greece)*

09.00-09.30 **Treatment of drug induced hyperthyroidism**  
**– focus on amiodarone and monoclonal antibodies**  
*Luigi Bartalena (Italy)*

### COFFEE BREAK

10.00-10.30 **Health outcomes related with hyperthyroidism:**  
**Low TSH: what is the evidence for harm?**  
*Simon Pearce (United Kingdom)*

10.30-11.00 **Health outcomes related with hyperthyroidism: Burden of cardiovascular morbidity and mortality risk in hyperthyroidism – Effect of treatment?**  
*Salman Razvi (United Kingdom)*

11.00-11.30 **Health outcomes with hyperthyroidism:**  
**How to evaluate clinical activity / severity of GO**  
*George J. Kahaly (Germany)*

### COFFEE BREAK

12.00-12.30 **Hyperthyroidism in pregnancy**  
**– when and how to treat with focus on the effect / consequences of treatment for the mother and child?**  
*Kris Poppe (Belgium)*

12.30-13.00 **Subclinical hyperthyroidism**  
**– who should be treated and choice of treatment?**  
*Kristien Boelaert (United Kingdom)*

# ETA Basic - Scientific Update 2018

VENUE  
**C9 The Kathrine  
Shears Studio**

**09.00 – 12.00**

Chair: Anita Boelen (The Netherlands)

---

09.00-09.30    **RNA seq/analysis**  
*Laurent Sachs (France)*

---

09.30-10.00    **Exome databases / exome sequencing**  
*Nadia Schoenmakers (United Kingdom)*

---

## COFFEE BREAK

---

10.30-11.00    **Mouse Cre lines**  
*Heike Heuer (Germany)*

---

11.00-11.30    **Genetically modified mice in studies of  
thyroid hormone physiology and action**  
*Graham Williams (United Kingdom)*

---

11.30-12.00    **Generation of tissue specific cells from iPSC**  
*Anthony Hollenberg (USA)*

---



# ETA-CRN Symposium

VENUE

Barbour Room EAST

08.00-13.00

## Medullary Thyroid Cancer Management

### 08.00 Welcome address

Dagmar Führer (Germany)

### SESSION I

Chair: Dagmar Führer (Germany)

08.10-08.30 **Calcitonin ranges, stimulation test and alternative markers**  
*Laura Fugazzola (Italy)*

08.30-08.50 **Cost effectiveness of Calcitonin screening**  
*Hans Verbeek (The Netherlands)*

08.50-09.15 **Surgical approaches depending on known RET germline mutation**  
*Agnieszka Czarniecka (Poland)*

09.15-09.40 **Surgical approaches depending on calcitonin and elective central and lateral neck compartment**  
*Schelto Kruijff (The Netherlands)*

09.40-10.05 **Long-term survivorship and RET genotypes**  
*Karin Frank-Raue (Germany)*

### COFFEE BREAK

### SESSION II

Chair: Markus Luster (Germany)

10.30-10.55 **Novel imaging techniques for MTC**  
*Arnoldo Piccardo (Italy)*

10.55-11.20 **Animal models in MTC**  
*Giovanni Vitale (Italy)*

11.20-11.45 **Immune components of MTC – „hype“ or perspectives?**  
*Rosa Marina Mellilo (Italy)*

11.45-12.15 **Perspectives in the management of MTC/MEN2A**  
*Sam Wells (USA)*

12.15-12.30 **Round Table discussion**

12.30 **Closing remarks and Lunch**

12.30-13.00 **General Assembly of ETA-CRN**



08.00-13.00

## Achieving Optimal Iodine Nutrition

08.00-08.25 Registration and Coffee/Tea

08.25-08.30 Introduction – John H. Lazarus (IGN Regional Coordinator)

Chairs:

Iris Erlund (Finland) &amp; Lluís Vila (Spain)

 08.30-08.50 **Dietary iodine intake: is it adequate nowadays ?**  
*Ian Givens (United Kingdom)*

 08.50-09.10 **Breast milk iodine**  
*Maria Andersson (Switzerland)*

 09.10-09.30 **Iodine nutrition in pregnant and lactating Norwegian women**  
*Sigrun Henjum (Norway)*

 09.30-09.50 **The role of surveys in assessment of iodine status**  
*Jayne Woodside (Northern Ireland)*

### COFFEE/TEA and POSTERS

Chairs:

Alicja Hubalewska-Dydejczyk (Poland) &amp; Henry Völzke (Germany)

 10.30-10.50 **Israel – country profile**  
*Aron Troen (Israel)*

 10.50-11.10 **Iodine and endocrine disruptors**  
*Barbara Demeneix (France)*

 11.10-11.30 **Milk iodine concentration in UK**  
*Simon Welham (United Kingdom)*

 11.30-11.50 **Iodine nutrition in Portuguese primary schools**  
*Inês Delgado (Portugal)*

 11.50-12.15 **Optimal iodine nutrition in Europe – are we getting there?**  
*John H. Lazarus (Wales)*

 12.15-13.00 **Lunch and Close**

## ULTRASOUND COURSE

08.30-13.00

VENUE  
**SAGE Two**


---

08.00-08.10    **Welcome, introduction to course and educational objectives**  
*Malcom Prentice, United Kingdom*

---

08.10-08.30    **Principles of US**  
*Colin Deane, United Kingdom*

---

08.30-08.45    **Demonstration - How to perform a US scan and basic anatomy of the neck**  
*David Richardson, United Kingdom*

---

08.45-10.00    **Hands on Session 1:**  
**Self/Normal thyroids (15 mins per candidate)**

---

10.00-10.30    **Risk stratification of thyroid nodules**  
*Paolo Vitti, Italy*

---

**COFFEE**


---

10.50-13.00    **Hands on Session 2:**  
**(Rotation) Patient thyroids and Hands on US guided FNAC on neck phantoms**

---

13.00            **Debrief and course evaluation**

---

13:45 - 14:00

**OPENING CEREMONY & WELCOME**

Pilar Santisteban and Simon Pearce

VENUE

**SAGE One**

14:00 - 16:00

**ORAL Session 1: Topic Highlights**

Chair(s): Pilar Santisteban (Spain) &amp; Simon Pearce (United Kingdom)

VENUE

**SAGE One**

14:00 - 14:15

**OP-01-01****Antigen-specific immune-modulation using TSH receptor peptides (ATX-GD-59) for Graves' hyperthyroidism: results of a 'first-in-human' study.***Simon Pearce (United Kingdom)*

14:20 - 14:35

**OP-01-02****Development of a recombinant FRET-based biosensor to assess compartment-specific T3 levels in live cells***Dorottya Németh (Hungary)*

14:40 - 14:55

**OP-01-03****Use of NanoString technology to define the immune profile of thyroid carcinoma***Efisio Puxeddu (Italy)*

15:00 - 15:15

**OP-01-04****Local control of thyroid hormone availability determines cell fate decisions in the adult neural stem niche***Cristina Luongo (France)*

15:20 - 15:35

**OP-01-05****Whole-genome methylation profiling of medullary thyroid cancer***Malgorzata Oczko-Wojciechowska (Poland)*

15:40 - 15:55

**OP-01-06****Thyroid hormone analog therapy in patients with MCT8 deficiency: the Triac Trial***Stefan Groeneweg (The Netherlands)*

16:00 - 17:00 Poster Discussion &amp; Coffee Break

**POSTER Discussion 1: P1-01-01 – P1-07-72**

VENUE

**Balcony****P1-01-01 - 10****Autoimmunity - 1***Chair: Paul Banga (United Kingdom)***P1-02-11 - 20****Case report 1***Chair: Carla Moran (United Kingdom)***P1-03-21 - 32****Diagnosis 1***Chair: Malgorzata Oczko-Wojciechowska (Poland)*



<b>P1-04-33 - 41</b>	<b>Epidemiology and Clinical Features</b> <i>Chair: Daria Handkiewicz-Junak (Poland)</i>
<b>P1-05-42 - 52</b>	<b>Hypothyroidism-1</b> <i>Chair: Salman Razvi (United Kingdom)</i>
<b>P1-06-53 - 63</b>	<b>Nodules-1</b> <i>Chair: Endre Nagy (Hungary)</i>
<b>P1-07-64 - 72</b>	<b>Thyroid Cancer</b> <i>Chair: Kalliopi Pazaitou-Panayiotou (Greece)</i>

17:00 - 18:00

**ETA Industry-sponsored Satellite SYMPOSIUM 1**VENUE  
**SAGE One****Pharmacokinetics & Bioequivalence of L-T4 compounds****WELCOME and INTRODUCTION**

George J. Kahaly (Germany) (5 Min)

**Pharmacokinetics, pharmacovigilance, bioequivalence and requirements of the European Agency (EMA) for L-T4 compounds**

Hans-Peter Lipp (Germany) (20 Min)

**FDA requirements and aimed 95 – 105 % range in the USA for L-T4 compounds**

James Hennessey (USA) (20 Min)

**Discussion** (15 Min)**MERCK (Global) organized and funded educational symposium**

18:15 - 19:00

**ETJ Lecture**

Chair: Wilmar Wiersinga (The Netherlands)

VENUE  
**SAGE One**

19:00 - 19:12

**TRIBUTE to Theo Visser**

Robin Peeters (The Netherlands)

VENUE  
**SAGE One**

19:15 - 19:45

**In remembrance of Reginald Hall Lecture**

Anthony Weetman (United Kingdom)

VENUE  
**SAGE One**

19:45 - 22:00

**WELCOME Reception**VENUE  
**Main Foyer**

07:00 - 08:00

**ETA Industry-sponsored Satellite SYMPOSIUM 2**VENUE  
**SAGE One****Can we achieve higher standards of care for patients with advanced RAI-R DTC? How good is your MDT?**

- 07:00 – 07:10 **Introduction Goal of the symposium and the panel**  
*Dr. Juan Carlos Galofré (Spain)*
- 07:10 – 07:20 **Introduction to case study Treatment of recurrent DTC**  
*Dr. Juan Carlos Galofré (Spain) & Dr. Markus Luster (Germany)*
- 07:20 – 07:30 **Continuation of the case study Monitoring of the RAI-R DTC patient – what does active surveillance actually look like**  
*Dr. Juan Carlos Galofré (Spain) & Dr. Rossella Elisei (Italy)*
- 07:30 – 07:40 **Continuation of the case study Preparation of the patient for potential TKI treatment**  
*Dr. Juan Carlos Galofré (Spain) & Dr. Marcia Brose (USA)*
- 07:40 – 07:50 **Continuation of the case study Supporting the patients on TKI therapy**
- 07:50 – 08:00 **Questions from the audience**  
*Dr. Juan Carlos Galofré (Spain)*
- 08:00 **Close**

EISAI organized and funded educational symposium

08:00 - 09:30

**SYMPOSIUM 1 (Translational)**VENUE  
**SAGE One****Selenium and thyroid disease**

Chair(s): Laszlo Hegedüs (Denmark) &amp; Margaret Rayman (United Kingdom)

- 08:00 - 08:30 **Current practice in use of selenium in Europe**  
*Kristian Winther (Denmark)*
- 08:30 - 09:00 **Selenium and thyroid disease susceptibility**  
*Margaret Rayman (United Kingdom)*
- 09:00 - 09:30 **Selenium and the thyroid - knowns and unknowns**  
*Lutz Schomburg (Germany)*

08:00 - 09:30

**SYMPOSIUM 2 (Basic)**VENUE  
**Barbour Room****Thyroid hormone action through time**

Chair(s): Laurent Sachs (France) &amp; Nadia Schoenmakers (United Kingdom)

- 08:00 - 08:30 **Evolution of thyroid hormone action**  
*Vincent Laudet (France)*
- 08:30 - 09:00 **Regulation of Thyroid hormone action during neuronal progenitor development**  
*Sylvie Remaud (France)*
- 09:00 - 09:30 **Thyroid hormone and eternal life?**  
*Anthony Hollenberg (USA)*

## 09:30 - 10:00 Coffee Break

10:00 - 12:00

### ORAL Session 2: Pregnancy, and inherited thyroid disease

VENUE  
**SAGE One**

Chair(s): Stine Linding Andersen (Denmark) & Bijay Vaidya (United Kingdom)

10:00 - 10:10	<b>OP-02-07</b> <b>Pregnancy week specific reference ranges for TSH and free T4 during early pregnancy in a cohort of 10,438 anti-TPO and anti-Tg negative Danish pregnant women</b> <i>Stine Linding Andersen (Denmark)</i>
10:15 - 10:25	<b>OP-02-08</b> <b>Effects of iodine nutrition of pregnant women on obstetric complication during pregnancy and intellectual development of offspring</b> <i>Zhongyan Shan (China)</i>
10:30 - 10:40	<b>OP-02-09</b> <b>Similarities and differences of dietary and other determinants of iodine status in pregnant women from three European birth cohorts</b> <i>Mariana Dineva (United Kingdom)</i>
10:45 - 10:55	<b>OP-02-10</b> <b>Controlled Antenatal Thyroid Screening (CATS) II: long-term cardiometabolic effects of treating maternal sub-optimal thyroid function</b> <i>Ilaria Muller (United Kingdom)</i>
11:00 - 11:10	<b>OP-02-11</b> <b>Reference ranges and determinants of thyroid function during pregnancy: the SELMA study</b> <i>Arash Derakhshan (The Netherlands)</i>
11:15 - 11:25	<b>OP-02-12</b> <b>The features of cytokine and steroid endometrium expression in women with autoimmune thyroid pathology and reproductive failures</b> <i>Ksenia Fris (Russian Federation)</i>
11:30 - 11:40	<b>OP-02-13</b> <b>Preconceptional thyrotropin level and reproductive outcome of in vitro fertilisation in healthy euthyroid women</b> <i>Diana Grove-Laugesen (Denmark)</i>
11:45 - 11:55	<b>OP-02-14</b> <b>Revisiting the diagnosis of Congenital Hypothyroidism: High incidence of thyroid dysfunction associated with mutations in DUOX2 and DUOX2 in infants undetected by current UK national newborn screening cut points</b> <i>Nadia Schoenmakers (United Kingdom)</i>

10:00 - 12:00

**ORAL Session 3: Targets of thyroid hormone action**VENUE  
**Barbour Room**

Chair(s): Krishna Chatterjee (United Kingdom) &amp; Samuel Refetoff (USA)

- |               |  |
|---------------|--|
| 10:00 - 10:10 | <b>OP-03-15</b><br><b>Exogenous hyperthyroidism induces osteocytic osteolysis in male mice</b><br><i>Elena Tsourdi (Germany)</i>   |
| 10:15 - 10:25 | <b>OP-03-16</b><br><b>Non-genomic effects of thyroid hormones on mesenchymal stem cells in tumour angiogenesis</b><br><i>Kathrin Schmohl (Germany)</i>   |
| 10:30 - 10:40 | <b>OP-03-17</b><br><b>Epigenetic Changes During Human Thyroid Cell Differentiation</b><br><i>Terry Davies (USA)</i>  |
| 10:45 - 10:55 | <b>OP-03-18</b><br><b>Hypothyroidism Sex-dependently Reverses Murine Gallstone Formation</b><br><i>Denise Zwanziger (Germany)</i>  |
| 11:00 - 11:10 | <b>OP-03-19</b><br><b>Beneficial effects of hypothyroidism on chronic pressure overload model in male mice</b><br><i>Helena Rakov (Germany)</i>  |
| 11:15 - 11:25 | <b>OP-03-20</b><br><b>A novel THRA M256T mutation lacking T3/T4 discrimination found in a resistance to thyroid hormone alpha patient</b><br><i>Karn Wejaphikul (The Netherlands)</i>                      |
| 11:30 - 11:40 | <b>OP-03-21</b><br><b>Protective and detrimental effects of experimental hypo- and hyperthyroidism on myocardial infarct size and functional recovery in mouse heart</b><br><i>Janina Gassen (Germany)</i> |
| 11:45 - 11:55 | <b>OP-03-22</b><br><b>The metabolic and thermoregulatory phenotype of mice lacking the thyroid hormone receptor beta</b><br><i>Lisbeth Harder (Germany)</i>  |

12:00 - 13:00 **Poster Discussion & Lunch****POSTER Discussion 2: P2-01-73 – P2-07-144**VENUE  
**Balcony**

- |                        |   |
|------------------------|---|
| <b>P2-01-73 - 83</b>   | <b>Diagnosis 2</b><br><i>Chair: Juan Carlos Galofré (Spain)</i>                       |
| <b>P2-02-84 - 93</b>   | <b>Graves' Orbitopathy</b><br><i>Chair: Marian Ludgate (United Kingdom)</i>           |
| <b>P2-03-94 - 103</b>  | <b>Hypothyroidism - 2</b><br><i>Chair: Orsolya Dohán (Hungary)</i>                    |
| <b>P2-04-104 - 114</b> | <b>Nodules-2</b><br><i>Chair: Gilles Russ (France)</i>                                |
| <b>P2-05-115 - 125</b> | <b>Thyroid Surgery and radioiodine</b><br><i>Chair: John Lazarus (United Kingdom)</i> |

---

**P2-06-126 - 134 Transport and Targets**

Chair: Lars Moeller (Germany)

---

**P2-07-135 - 144 Treatment**

Chair: Rodrigo Moreno Reyes (The Netherlands)

---

**13:00 - 14:00****ETA Industry-sponsored Satellite SYMPOSIUM 3**

VENUE  
**SAGE One**

**Thyroid Update**

Chair: George J. Kahaly (Germany)

13:00-13:05 **Welcome Address and Introduction**

*George J Kahaly (Germany)*

13:05-13:20 **Genomic Profile of Thyroid Cancer**

*Pilar Santisteban (Spain)*

13:20-13:35 **Immune Reconstitution Thyroiditis**

*Colin Dayan (United Kingdom)*

13:35-13:50 **Iodinated contrast media-induced hyperthyroidism**

*Tomasz Bednarczuk (Poland)*

13:50-14:00 **General Discussion**

**BERLIN CHEMIE** organized and funded educational symposium

SUNDAY  
Scientific Programme

**14:00 - 14:45****Meet the  
EXPERT 1**

VENUE  
**SAGE One**

**Clinical impact of thyroid function  
variation within the reference range**

*Peter Taylor (United Kingdom)*

**14:00 - 14:45****Meet the  
EXPERT 2**

VENUE  
**Barbour Room**

**Noninvasive follicular thyroid  
neoplasm with papillary-like nuclear  
features (NIFTP): A changing  
paradigm in thyroid pathology**

*Fulvio Basolo (Italy)*

**14:00 - 14:45****Meet the  
EXPERT 3**

VENUE  
**C9 The Kathrine  
Shears Studio**

**Thyroid hormone analogues,  
antagonists and inhibitors**

*Riccardo Zucchi (Italy)*

**14:00 - 14:45****Meet the  
EXPERT 4**

VENUE  
**SAGE Two**

**Thyroid hormone, metabolism  
and longevity**

*Marie-Stéphanie Clerget-Froidevaux  
(France)*

**14:45 - 15:00 Coffee Break**

15:00 - 17:00

**Oral Session 4: Thyroid dysfunction**

VENUE

**SAGE One**

Chair(s): Eric Fliers (The Netherlands) &amp; Anthony Hollenberg (USA)

- 
- 15:00 - 15:10 **OP-04-23**  
**The influence of metformin and hypocaloric dieting on thyroid iodide uptake in healthy volunteers: a pilot study.**  
*Yvette Sloot (The Netherlands)*
- 
- 15:15 - 15:25 **OP-04-24**  
**Trends, Determinants and Associations of Treated Hypothyroidism in the United Kingdom, 2005 - 2014**  
*Salman Razvi (United Kingdom)*
- 
- 15:30 - 15:40 **OP-04-25**  
**Hyperthyroidism increases the risk of dementia, which partially relates to pre-existing morbidity - A register based cohort study of two large cohorts**  
*Lars Folkestad (Denmark)*
- 
- 15:45 - 15:55 **OP-04-26**  
**Thyroid hormone levels are associated with left ventricular structure derived from MRI in two population-based studies**  
*Till Ittermann (Germany)*
- 
- 16:00 - 16:10 **OP-04-27**  
**Does mental vulnerability determine thyroid disease or vice versa?**  
*Lena Bjergved (Denmark)*
- 
- 16:15 - 16:25 **OP-04-28**  
**Reduced sensitivity to thyroid hormone as a transgenerational epigenetic phenomenon transmitted along the male line**  
*Joao Anselmo (Portugal)*
- 
- 16:30 - 16:40 **OP-04-29**  
**Dual effects of thyroid-stimulating hormone on metabolic syndrome and its components in euthyroid adults: a population-based thyroid study**  
*Haoyu Wang (China)*
- 
- 16:45 - 16:55 **OP-04-30**  
**Impaired quality of life after radioiodine compared with anti-thyroid or surgery treatment for Graves' hyperthyroidism. A long-term follow-up with ThyPRO and SF-36.**  
*Göran Wallin (Sweden)*
- 

15:00 - 17:00

**ORAL Session 5: Thyroid cancer basic**

VENUE

**Barbour Room**

Chair(s): Christopher McCabe (United Kingdom) &amp; Paula Soares (Portugal)

- 
- 15:00 - 15:10 **OP-05-31**  
**Unsaturated fatty acid synthesis is a metabolic feature of thyroid cancer-associated macrophages**  
*Katrin Rabold (The Netherlands)*
-



15:15 - 15:25	<b>OP-05-32</b> <b>CXCL9 and CXCL11 chemokines modulation by IFN-gamma, TNF-alpha and PPAR-gamma in Papillary Thyroid Cancer</b> <i>Silvia Martina Ferrari (Italy)</i>
15:30 - 15:40	<b>OP-05-33</b> <b>Expression of TERT in papillary thyroid cancer and biological effects of hTERT silencing in human papillary thyroid cancer cells</b> <i>Marilena Celano (Italy)</i>
15:45 - 15:55	<b>OP-05-34</b> <b>VAV3 acts as a tumor suppressor in thyroid cancer</b> <i>Miguel Zaballo (Spain)</i>
16:00 - 16:10	<b>OP-05-35</b> <b>Embryonic thyroid cells resist BRAFV600E-induced dedifferentiation</b> <i>Shawn Liang (Sweden)</i>
16:15 - 16:25	<b>OP-05-36</b> <b>Dependence of thyroid tumorigenesis on miRNA processing by Dicer1 in vivo</b> <i>Elin Schoultz (Sweden)</i>
16:30 - 16:40	<b>OP-05-37</b> <b>Proteomic changes in benign follicular adenoma versus malignant follicular variant of papillary thyroid carcinoma</b> <i>Corin Badiu (Romania)</i>
16:45 - 16:55	<b>OP-05-38</b> <b>The six1 homeoprotein regulates the suppressive and oncogenic effect of tgfb pathway</b> <i>Adrian Acuña (Spain)</i>

17:00 - 18:00

## ETA Industry-sponsored Satellite SYMPOSIUM 4

VENUE  
SAGE One

### Latest Developments on Thyroid Cancer Management

Chair: Rossella Elisei (Italy)

### Radioactive Iodine Therapy of Thyroid Cancer Patients with Lymph Node Involvement

Claire Bournaud (France)

### Management of Advanced Medullary Thyroid Cancer

Jonathan Wadsley (United Kingdom)

Sanofi Genzyme organized and funded educational symposium

18:00 - 18:40

## Harrington-de Visscher Prize Lecture

Chair(s): Pilar Santisteban (Spain) and Colin Dayan (United Kingdom)

VENUE  
SAGE One

07:00 - 08:00

**ETA Industry-sponsored Satellite SYMPOSIUM 5**VENUE  
**SAGE One****TSH Receptor Functional Antibodies – An Update**

- 07:00 – 07:05 **Welcome address and introduction**  
*George J Kahaly (Germany)*
- 07:05 – 07:20 **TSH Receptor: Structure and Function**  
*Simon H Pearce (United Kingdom)*
- 07:20 – 07:35 **TSH Receptor Functional Antibodies**  
*George J Kahaly (Germany)*
- 07:35 – 07:50 **TSH Receptor Blocking Antibodies**  
*Tanja Diana (Germany)*
- 07:50 – 08:00 **General Discussion**  
*Moderation: George J Kahaly*

**GUIDEL organized and funded educational symposium**

08:00 - 09:30

**SYMPOSIUM 3 (Clinical)**VENUE  
**SAGE One****Thyroid cancer at different ages**

Chair(s): Laurence Leenhardt (France) &amp; Thera Links (The Netherlands)

- 08:00 - 08:30 **Histological and molecular age related differences**  
*Paula Soares (Portugal)*
- 08:30 - 09:00 **Paediatric differentiated thyroid cancer: outcomes of treatment**  
*Thera Links (The Netherlands)*
- 09:00 - 09:30 **Therapeutic management and quality of life in the elderly**  
*Daria Handkiewicz-Junak (Poland)*

08:00 - 09:30

**SYMPOSIUM 4 (Translational)**VENUE  
**Barbour Room****The future is in vivo**

Chair(s): Monica Dentice (Italy) &amp; Jens Mittag (Germany)

- 08:00 - 08:30 **Cell specific targeting of thyroid hormone receptors in zebrafish model**  
*Federica Marelli (Italy)*
- 08:30 - 09:00 **Cell specific targeting of thyroid hormone transporters**  
*Heike Heuer (Germany)*
- 09:00 - 09:30 **Cell specific targeting of thyroid hormone metabolism**  
*John Howard Duncan Bassett (United Kingdom)*

**09:30 - 10:00 Coffee Break**

10:00 - 12:00

**ORAL Session 6: Update in treatment of Thyroid Cancer**

VENUE  
**SAGE One**

Chair(s): Sophie Leboulleux (France) & Petros Perros (United Kingdom)

- 
- 10:00 - 10:10 **OP-06-39**  
**Active surveillance in low risk papillary thyroid carcinoma:  
A multicenter cohort study in Korea**  
*Hye-Seon Oh (Republic of South Korea)*
- 
- 10:15 - 10:25 **OP-06-40**  
**Hypothalamic-pituitary-adrenal axis dysfunction in patients receiving  
tyrosine-kinase inhibitors for advanced thyroid cancer**  
*Carla Colombo (Italy)*
- 
- 10:30 - 10:40 **OP-06-41**  
**Recombinant human thyrotropin vs thyroid hormone withdrawal in  
radioactive iodine therapy of thyroid cancer patients with nodal metastatic  
disease: a large multicenter retrospective matched cohort study**  
*Laurence Leenhardt (France)*
- 
- 10:45 - 10:55 **OP-06-42**  
**Tailoring Lenvatinib treatment to increase response  
and to lower side effects**  
*Simone de Leo (Italy)*
- 
- 11:00 - 11:10 **OP-06-43**  
**Efficacy of tyrosine-kinase inhibitors (TKI) as second-line treatment  
in advanced thyroid cancer**  
*Filomena Barbato (Italy)*
- 
- 11:15 - 11:25 **OP-06-44**  
**Radiiodine treatment after thyroid hormone withdrawal or rhTSH  
stimulation – a single centre retrospective study in disseminated  
thyroid cancer in paediatric patients**  
*Daria Handkiewicz-Junak (Poland)*
- 
- 11:30 - 11:40 **OP-06-45**  
**Papillary microcarcinomas (PMC):  
active surveillance and its impact on the quality of life**  
*Maria Cristina Campopiano (Italy)*
- 
- 11:45 - 11:55 **OP-06-46**  
**Papillary thyroid (cT1aN0) micro-carcinomas managed with  
ultrasound-guided percutaneous ethanol ablation (UPEA):  
an effective alternative to neck surgery or observation**  
*Ian Hay (USA)*
- 

10:00 - 12:00

**ORAL Session 7: Thyroid Hormone Metabolism  
and Transport**

VENUE  
**Barbour Room**

Chair(s): Balázs Gereben (Hungary) & Graham Williams (United Kingdom)

- 
- 10:00 - 10:10 **OP-07-47**  
**Corticosterone affects thyroid hormones induced modification  
of the methylome**  
*Laurent Sachs (France)*
-

10:15 - 10:25	<b>OP-07-48</b> <b>The upregulation of eNOS and NOX2, two target proteins of Caveolin-1, and of Deiodinase 3 is involved in the oxidative stress of Grave's orbital adipocytes</b> <i>Marie-Christine Many (Belgium)</i>
10:30 - 10:40	<b>OP-07-49</b> <b>An epigenetic mechanism is involved in the effect of high iodine treatment during thyroid differentiation in development</b> <i>Jesús Morillo (Spain)</i>
10:45 - 10:55	<b>OP-07-50</b> <b>Thyromimetic potential of novel TH analogs in primary neurons and in TH transporter deficient mice</b> <i>Eva Salveridou (Germany)</i>
11:00 - 11:10	<b>OP-07-51</b> <b>3-iodothyronamine ameliorates ischemia-induced synaptic dysfunction in mouse entorhinal cortex</b> <i>Riccardo Zucchi (Italy)</i>
11:15 - 11:25	<b>OP-07-52</b> <b>Deiodinase type 2 knockout zebrafish display hyperglycemia and signs of insulin resistance, associated with diabetes mellitus type 2</b> <i>Veerle Darras (Belgium)</i>
11:30 - 11:40	<b>OP-07-53</b> <b>The thyroid hormone receptor <math>\beta</math> depletes the breast cancer stem cell population in estrogen-dependent MCF-7 cells</b> <i>Irene López-Mateo (Spain)</i>
11:45 - 11:55	<b>OP-07-54</b> <b>Identification of thyroid hormone transporters in a human placental cell model</b> <i>Zhongli Chen (The Netherlands)</i>

**12:00 - 13:00 Poster Discussion & Lunch****POSTER Discussion 3: P3-01-145 – P3-07-210**

VENUE  
**Balcony**

<b>P3-01-145 – 154</b>	<b>Autoimmunity-2</b> <i>Chair: Michele Marino (Italy)</i>
<b>P3-02-155 – 159</b>	<b>Basic and Translational</b> <i>Chair: Cristina Romei (Italy)</i>
<b>P3-03-160 – 169</b>	<b>Case Reports and Clinical Features</b> <i>Chair: Maria Grazia Castagna (Italy)</i>
<b>P3-04-170 – 180</b>	<b>Diagnosis + Treatment</b> <i>Chair: Gabriella Pellegriti (Italy)</i>
<b>P3-05-181 – 190</b>	<b>Nodules-3</b> <i>Chair: Ulla Feldt-Rasmussen (Denmark)</i>
<b>P3-06-191 – 200</b>	<b>Pregnancy, Iodine and rare diseases</b> <i>Chair: Kristien Boelaert (Denmark)</i>
<b>P3-07-201 – 210</b>	<b>Thyroid disease</b> <i>Chair: Barbara Demeneix (France)</i>

13:00 - 14:00

## ETA Industry-sponsored Satellite SYMPOSIUM 6

VENUE  
SAGE One

### Experience in action: RAI-R DTC in 2018

13:00 – 13:10 **RAI-R DTC: the current state of play**

*Chair: Sophie Leboulleux (France)*

13:10 – 13:30 **Confidence through experience:  
starting systemic therapy**

*Johannes Smit (The Netherlands)*

13:30 – 13:55 **Practical insights:  
supporting our patients on their treatment journey**

*Marcia Brose (USA)*

13:55 – 14:00 **Summary of key insights**

*All Moderated by the chair*

**BAYER organized and funded educational symposium**

14:00 - 14:45

Meet the  
EXPERT **5**

VENUE  
SAGE One

**Diagnostic imaging in thyroid nodules**

*Gilles Russ (France)*

14:00 - 14:45

Meet the  
EXPERT **6**

VENUE  
Barbour Room

**Artefacts, interference and new  
assays for thyroid function testing**

*Mark Gurnell (United Kingdom)*

14:00 - 14:45

Meet the  
EXPERT **7**

VENUE  
C9 The Kathrine  
Shears Studio

**Visualising thyroid hormone action  
in vivo**

*Balázs Gereben (Hungary)*

14:00 - 14:45

Meet the  
EXPERT **8**

VENUE  
SAGE Two

**Immunotherapy for advanced  
thyroid cancer**

*Efisio Puxeddu (Italy)*

14:45 - 15:00 **Coffee Break**

15:00 - 17:00

**ORAL Session 8: Autoimmunity,  
Graves' Orbitopathy, Genetics**VENUE  
**SAGE One**

Chair(s): Mark Vanderpump (United Kingdom) &amp; Milos Zarkovic (Serbia)

- 
- 15:00 - 15:10 **OP-08-55**  
**T and B cells infiltrating orbital tissues in Graves' Orbitopathy (GO) and their relation with GO activity. A possible explanation for GO response to immunosuppressive treatments**  
*Michele Marino (Italy)*
- 
- 15:15 - 15:25 **OP-08-56**  
**Dilution analysis of thyroid stimulating antibodies differentiates between Graves' thyroidal and orbital disease**  
*Tanja Diana (Germany)*
- 
- 15:30 - 15:40 **OP-08-57**  
**Blocking the TSH receptor with the human monoclonal autoantibody K1-70(TM) improves Graves' ophthalmopathy and aids control of advanced follicular thyroid carcinoma - results of long-term treatment under the first in human single patient expanded use therapy**  
*Jadwiga Furmaniak (United Kingdom)*
- 
- 15:45 - 15:55 **OP-08-58**  
**The optimal iodine intake is the protective factor for the positive thyroid autoantibodies: An epidemiological survey of 31 provinces in China**  
*Weiping Teng (China)*
- 
- 16:00 - 16:10 **OP-08-59**  
**Death by suicide is increased in patients with Hashimoto's thyroiditis. A nationwide register-based study**  
*Marianne Thvilum (Denmark)*
- 
- 16:15 - 16:25 **OP-08-60**  
**Comparison of the treatment effect between thiamazole and potassium iodide for newly diagnosed Graves' disease**  
*Nami Suzuki (Japan)*
- 
- 16:30 - 16:40 **OP-08-61**  
**Thyroid dysfunction during PD-1 blockade treatment have important role in predicting the efficacy of PD-1 blockade in addition to PD-L1 expression**  
*Hye In Kim (Republic of South Korea)*
- 
- 16:45 - 16:55 **OP-08-62**  
**Investigation of Novel biomarkers and Definition of role of the microbiome in Graves' Orbitopathy (INDIGO): the probiotic trial**  
*Mario Salvi (Italy)*
-



15:00 - 17:00

**ORAL Session 9: Thyroid cancer translational**

VENUE  
**Barbour Room**

Chair(s): Cosimo Durante (Italy) & Dagmar Führer-Sakel (Germany)

- |               |  |
|---------------|--|
| 15:00 - 15:10 | <b>OP-09-63</b><br><b>TERT promoter mutations and their association with factors of poor prognosis in papillary thyroid carcinoma- based on Polish patients</b><br><i>Dagmara Rusinek (Poland)</i> |
| 15:15 - 15:25 | <b>OP-09-64</b><br><b>Molecular profiling of thyroid nodule fine-needle aspiration cytology through PTC Mass Array genotyping platform</b><br><i>Marina Muzza (Italy)</i>                          |
| 15:30 - 15:40 | <b>OP-09-65</b><br><b>Hyperthyroidism and papillary thyroid carcinoma in thyroid stimulating hormone receptor D633H mutant mice</b><br><i>Holger Jäschke (Germany)</i>                             |
| 15:45 - 15:55 | <b>OP-09-66</b><br><b>Mutational Profile of a Large Series of Sporadic Medullary Thyroid Carcinomas by Next Generation Targeted Sequencing</b><br><i>Raffaele Ciampi (Italy)</i>                   |
| 16:00 - 16:10 | <b>OP-09-67</b><br><b>Targeting Claudin-1 Overexpressing Papillary Thyroid Carcinoma by Modified Clostridium Perfringens Enterotoxin</b><br><i>Denise Zwanziger (Germany)</i>                      |
| 16:15 - 16:25 | <b>OP-09-68</b><br><b>Genetic variants of PARP4 gene in patients affected with multiple primary tumors including thyroid cancers</b><br><i>Valentina Cirello (Italy)</i>                           |
| 16:30 - 16:40 | <b>OP-09-69</b><br><b>Multinodular goiter in childhood: a diagnostic gateway for screening DICER1 syndrome</b><br><i>Frederique Savagner (France)</i>  |
| 16:45 - 16:55 | <b>OP-09-70</b><br><b>The Comparison of Clinical and Genetic Features between Pediatric and Adult Papillary Thyroid Carcinomas</b><br><i>Vlasta Sykorova (Czech Republic)</i>                      |

17:10 - 17:50

**PINCHERA PRIZE Lecture**

VENUE  
**SAGE One**

Chair(s): Pilar Santisteban (Spain) & Colin Dayan (United Kingdom)

18:00 - 19:15

**GENERAL ASSEMBLY**

VENUE  
**SAGE One**

07:00 - 08:00

**Short Call Abstracts**

Chair: Leonidas Duntas (Greece)

VENUE  
**SAGE One**

08:00 - 08:25

**RESEARCH GRANT 2016 - Winner Presentations**

Chair(s): Colin Dayan (United Kingdom)

VENUE  
**SAGE One**

- 
- 08:00 - 08:08 **Role of the NADPH oxydase 4 (NOX4) in the repression of the SLC5A5 gene encoding the Sodium/Iodide Symporter (NIS) in BRAFV600E-mutated papillary thyroid cancers.**  
*Camille Buffet (France)*
- 
- 08:08 - 08:16 **The regulation of type 3 deiodinase during inflammation**  
*Anita Boelen (The Netherlands)*
- 
- 08:16 - 08:25 **A novel iodine-129 tracer method to quantify iodine absorption, retention and excretion in humans**  
*Valeria Galetti (Switzerland)*
- 

08:30 - 10:30

**ORAL Session 10: Young Investigators /  
Clinical + Translational**

Chair(s): Colin Dayan (United Kingdom) &amp; Leonidas Duntas (Greece)

VENUE  
**SAGE One**

- 
- 08:30 - 08:44 **OP-10-71**  
**Duration of hyperthyroidism and lack of treatment are associated with increased risk of cardiovascular disease and death.**  
*Mads Lillevang-Johansen (Denmark)*
- 
- 08:49 - 09:03 **OP-10-72**  
**Digoxin treatment induces tumor redifferentiation and augments radioactive iodide uptake in a mouse model of BrafV600E-induced thyroid cancer**  
*Marika Tesselaar (The Netherlands)*
- 
- 09:08 - 09:22 **OP-10-73**  
**Maternal iodine status and child IQ: a meta-analysis of individual-participant data from three population-based birth cohorts**  
*Deborah Levie (The Netherlands)*
- 
- 09:27 - 09:41 **OP-10-74**  
**Repeated momentary measurements of thyroid-related quality of life via a smartphone application**  
*Victor Brun Boesen (Denmark)*
- 
- 09:46 - 10:00 **OP-10-75**  
**Lenvatinib Therapy in Progressive, Radioiodine-Refractory, Differentiated Thyroid Carcinoma: analysis of 74 cases followed in a single centre**  
*Carlotta Giani (Italy)*
- 
- 10:05 - 10:19 **OP-10-76**  
**Circulating tumour DNA as a potential disease progression biomarker for advanced thyroid cancer**  
*David Allin (United Kingdom)*
-

08:30 - 10:30

**ORAL Session 11: Young Investigators / Basic**VENUE  
**Barbour Room**

Chair(s): J. H. Duncan Bassett (United Kingdom) &amp; Balázs Gereben (Hungary)

08:30 - 08:44 **OP-11-77****Gestational and early postnatal hypothyroidism arrest angiogenesis and lymphatic system development in the neocortex of rats***Federico S. Lucia (Spain)*08:49 - 09:03 **OP-11-78****Rapid vasodilation is a physiological effect of noncanonical thyroid hormone receptor alpha action***Daniela Geist (Germany)*09:08 - 09:22 **OP-11-79****Browning of white adipose tissue is mediated by canonical thyroid hormone receptor beta signaling***Sebastian Hoenes (Germany)*09:27 - 09:41 **OP-11-80****Ectopic expression of the human TRbeta2 affects the commitment of L-cone identity in the zebrafish, in an isoform-specific manner***Federica Marelli (Italy)*09:46 - 10:00 **OP-11-81****TAZ/WWTR1 and Pax8 elicit a crosstalk mechanism on NIS expression and function***Celia Fernández Méndez (Spain)*10:05 - 10:19 **OP-11-82****MCT8 deficiency disturbs early retinal development and results in a shift to more blue light-sensitive cones at the expense of green/red light-sensitive cones***Pieter Vancamp (Belgium)***10:30 - 11:00 Coffee Break & Lunch**

11:00 - 13:00

**ORAL Session 12: Clinical features and diagnostic approach of thyroid cancer**VENUE  
**SAGE One**

Chair(s): Laura Fugazzola (Italy) &amp; Johannes W. A. Smit (The Netherlands)

11:00 - 11:10 **OP-12-83****Is serum TSH a marker of thyroid carcinoma in patients with thyroid nodular disease? - A Danish multicentre study***Kristine Zøylner Swan (Denmark)*11:15 - 11:25 **OP-12-84****Calcitonin doubling time (CT-DT) may not be indicative of disease progression and survival in patients with metastatic Medullary Thyroid Carcinoma (MTC)***George Simeakis (Greece)*11:30 - 11:40 **OP-12-85****Presentation and clinical outcome of familial non-medullary thyroid carcinoma (FNMTc) according to the number of affected family members***Noemi Fralassi (Italy)*

11:45 - 11:55	<b>OP-12-86</b> <b>Familiarity as a new prognostic factor in the risk stratification of thyroid microcarcinoma</b> <i>Chiara Secchi (Italy)</i>
12:00 - 12:10	<b>OP-12-87</b> <b>Recurrence rates after low dose radioiodine ablation for differentiated thyroid cancer within a multicentre randomized trial</b> <i>Ujjal Mallick (United Kingdom)</i>
12:15 - 12:25	<b>OP-12-88</b> <b>Obesity and Differentiated Thyroid Cancer (DTC): correlation between Body Mass Index (BMI) and histopathological features</b> <i>Marianna Beghini (Italy)</i>
12:30 - 12:40	<b>OP-12-89</b> <b>Predictors of persistent or recurrent disease in 4,292 patients with differentiated thyroid cancer</b> <i>Gabriella Pellegriti (Italy)</i>
12:45 - 12:55	<b>OP-12-90</b> <b>Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): impact of the reclassification for the risk of malignancy in the Bethesda System for Reporting Thyroid Cytopathology</b> <i>Mara Ventura (Portugal)</i>

11:00 - 13:00

**ORAL Session 13: The thyroid and thyroid hormone**VENUE  
**Barbour Room**

Chair(s): Simon Pearce (United Kingdom) &amp; Domenico Salvatore (Italy)

11:00 - 11:10	<b>OP-13-91</b> <b>Crystal structure of ligand-free TSH receptor</b> <i>Jennifer Miller-Gallacher (United Kingdom)</i>
11:15 - 11:25	<b>OP-13-92</b> <b>Pro-inflammatory effect of Hyaluronan oligosaccharides (6-mer-HA) in human thyrocytes and fibroblasts: role of Toll-like 2 (TLR-2) and 4 (TLR-4) receptors</b> <i>Rosaria Ruggeri (Italy)</i>
11:30 - 11:40	<b>OP-13-93</b> <b>Class III PI3K/Vps34 is crucial for thyroid hormonogenesis</b> <i>Christophe Pierreux (Belgium)</i>
11:45 - 11:55	<b>OP-13-94</b> <b>Complex chromosomal rearrangement and segmental maternal UPD at chromosome 7 in a patient with Pendred Syndrome and Silver-Russell Syndrome-like features</b> <i>Valentina Cirello (Italy)</i>
12:00 - 12:10	<b>OP-13-95</b> <b>Partial thyrocyte-specific G protein alpha s deficiency leads to severe hypothyroidism, hyperplasia and papillary thyroid carcinoma-like lesions in mice</b> <i>Konrad Patyra (Finland)</i>

12:15 - 12:25	<b>OP-13-96</b> <b>Sox9 regulates Wnt/Beta-catenin pathway activity through modulation of TCF4 in thyroid follicular cells</b> <i>Carlos Carrasco López (Spain)</i>
12:30 - 12:40	<b>OP-13-97</b> <b>A feedback loop between the tumor suppressor DICER1 and thyroid differentiation transcription factors plays an important role in thyroid tumorigenesis</b> <i>Julia A. Ramirez-Moya (Spain)</i>
12:45 - 12:55	<b>OP-13-98</b> <b>Unraveling the Sonic-Hedgehog-Gli3 pathway involvement in the specification of the thyroid gland in zebrafish and in the pathogenesis of congenital hypothyroidism</b> <i>Giuditta Rurale (Italy)</i>

13:10 - 14:40

**SYMPOSIUM 5** (Clinical) Treating thyroid disease in pregnancy: new evidence on benefits and risks

VENUE  
**SAGE One**

Chair(s): Alicja Hubalewska-Dydejczyk (Poland) & Peter Taylor (United Kingdom)

13:10 - 13:40	<b>Current obstetric practice</b> <i>Ines Velasco (Spain)</i>
13:40 - 14:10	<b>Foetal outcomes</b> <i>Tim Korevaar (The Netherlands)</i>
14:10 - 14:40	<b>Obstetric outcomes</b> <i>Kristien Boelaert (United Kingdom)</i>

13:10 - 14:40

**SYMPOSIUM 6** (Basic) Recent advances in thyroid cancer research

VENUE  
**Barbour Room**

Chair(s): Miguel Melo (Portugal) & Garcilaso Riesco-Eizaguirre (Spain)

13:10 - 13:40	<b>Thyroid cancer heterogeneity</b> <i>Laura Fugazzola (Italy)</i>
13:40 - 14:10	<b>Epigenetic mechanisms in thyroid cancer</b> <i>Mercedes Robledo (Spain)</i>
14:10 - 14:40	<b>Thyroid cancer stem cells</b> <i>Giorgio Stassi (Italy)</i>

14:40 - 15:00

**PRIZE CEREMONY and Closure**

VENUE  
**SAGE One**

Chair(s): Laszlo Hegedüs (ETA President) & Leonidas Duntas (ETA Secretary)

TUESDAY


Scientific Programme

## Transparency Declaration

The Executive Committee and the Standing Office of the ETA are most grateful to the following ETA Corporate members and all other sponsors for their generous logistical support of the ETA 2018 Annual Meeting

AmCad BioMed Corporation	4.000 € for an exhibition space
Bayer HealthCare Pharmaceuticals Inc.	30.000 € for a satellite symposium
Berlin Chemie AG	30.000 € for a satellite symposium
BioScientifica Ltd.	3.000 € for an exhibition space
Eisai Europe Ltd	15.000 € for a satellite symposium
GE Healthcare	Provision of ultrasound machines
Hitachi Medical Systems	Provision of ultrasound machines
IBSA Institut Biochimique SA	6.000 € for an exhibition space
Merck	30.000 € for a satellite symposium 7.500 € for an exhibition space ETA Pinchera Prize: the sponsorship comprises the value of 3.000 € for the prize plus reimbursement of the travel expenses (economy class flights) and congress registration fee
Philips	Provision of ultrasound machines
Quidel	15.000 € for a satellite symposium 3.000 € for an exhibition space
RF Medical Co. Ltd., Korea	4.000 € for an exhibition space
Sanofi Genzyme	30.000 € for a satellite symposium 9.000 € for an exhibition space
Siemens Healthineers	Provision of ultrasound machines
STARmed Co., Ltd.	4.000 € for an exhibition space Provision of lanyards






**Sage Gateshead,  
Northern Rock  
Foundation Hall**



## Sage One Level 1

- |    |                     |
|----|---------------------|
| 2. | Quidel              |
| 3. | BioScientifica Ltd. |
| 4. | Karger              |
| 5. | ATA                 |
| 6. | TCSA                |
| 7. | TFI                 |
| 8. | TCA                 |
| 9. | BTF                 |





ETA 2019  
Budapest  
7.-10. Sept

**ETA** ★ European  
★ THYROID  
★ Association

**42nd Annual Meeting**  
**2019 BUDAPEST, HUNGARY**